Nucleos(t)ide analogues (NUCs) have been developed over the past decade and currently play a crucial role in the treatment of chronic hepatitis B infections. Studies show that, patients that test negative for the hepatitis B e antigen (HBeAg) may be cured by stopping NUC therapy, however this is seldom done in clinical practice.
- Where do the current guidelines stand on the discontinuation of NUC therapy in different patient populations?
- What does the data say about the role of flare-ups after treatment is stopped?
- Which parameters exist for predicting a functional cure following treatment cessation?
Join the faculty in this EASL Studio JHEP Live episode discussing an Expert opinion article published last year in the Journal of Hepatology.
If you are interested in the topic of Viral Hepatitis, watch these related episodes:
Special Edition: Live from Viral Hepatitis Elimination Conference 2022
This EASL studio is supported by GlaxoSmithKline. EASL has received no input from GlaxoSmithKline with regards to the content of this programme.
ℹ️ Please click here to access the podcast version of this EASL Studio episode.